Illumina delivered strong Q3 2025 results, with revenue of $1.08 billion, flat year-over-year, and diluted EPS of $0.98. Non-GAAP diluted EPS reached $1.34, surpassing expectations. The company returned to growth outside of China, driven by acceleration in the clinical market segment.
Revenue for Q3 2025 was $1.08 billion, remaining flat compared to Q3 2024 on both a reported and constant currency basis.
GAAP diluted EPS was $0.98, and non-GAAP diluted EPS was $1.34, exceeding the high-end of guidance.
GAAP operating margin stood at 21.0%, while non-GAAP operating margin was 24.5% for the quarter.
The company generated $284 million in cash from operations and $253 million in free cash flow during Q3 2025.
For fiscal year 2025, Illumina has raised its guidance for total company constant currency revenue, non-GAAP operating margin, and non-GAAP diluted EPS, while maintaining its revenue growth outlook outside of China.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance